Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials
Tarih
2013Yazar
LIEW, S. H. Melissa
Tugal-Tutkun, Ilknur
ZIERHUT, Manfred
BEZLYAK, Vladimir
Androudi, Sofia
Dick, Andrew D.
Foster, Stephen
Üst veri
Tüm öğe kaydını gösterÖzet
Purpose: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis.
Koleksiyonlar
- Makale [92796]